Stoke Therapeutics Inc. (STOK) Announces Proposed $75M Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Nasdaq, S&P 500 futures rise ahead of key jobs report
- Oil rallies for the week as U.S.-Iran fighting resumes; diesel hits record high
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- Fed’s Waller open to September rate hold - if disinflation holds up
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Stoke Therapeutics Announces Proposed Public Offering
March 26, 2024 4:07 PM EDTBEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock. In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of... More
